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1. Introduction 
Gene therapy is often attempted in fatal diseases with no known cure, or after standard 
therapies have failed. Targeting gene defects includes addressing a single mutation, 
multiple mutations in several genes, or even addressing missing or extra copies in a 
particular disease. A defect in one specific gene may impair normal function of the 
corresponding expressed protein. For example, in X-linked severe combined 
immunodeficiency (X-SCID), there is a mutation in the IL2 receptor Ǆ gene. Another classic 
example occurs in thalassemia propagated by a defect in the ǃ-globulin gene. Some diseases 
are caused by multiple mutations in several genes. For example, some cardiovascular 
diseases may manifest due to mutations in different chromosomes which are a result of 
inherited or environmental factors. Before approaching a disease using gene therapy, the 
key protein(s) and pathways involved in the disease should first be identified. However, in 
some cases an abnormal gene is formed that results in disease; such is the case for the Bcr-
Abl gene. The oncogenic Bcr-Abl protein is the causative agent of chronic myelogenous 
leukemia (CML) which could be blocked for CML treatment. Genomic sequencing 
information, microarrays, and biochemical assays can be used to determine up- or down-
regulated proteins involved in disease, and will help determine the function of these 
proteins. In the case of some cancers, the signal transduction pathways for oncogenesis have 
been mapped out, allowing hub proteins to be identified. Hub proteins are essential proteins 
that interact with multiple other proteins in signaling cascades. If selected properly, adding 
back a tumor-suppressing hub protein (such as p53), or blocking an oncogenic hub protein 
(such as survivin) could halt cancer or alter disease progression. Gene mutations can result 
in mislocalization of these key proteins which can cause cancer; this mislocalization can be 
exploited with gene therapy approaches. Further, new types of gene therapy are being 
developed in our lab to direct proteins to other cellular compartments where their function 
is altered. This chapter will summarize these and other known targets and also focus on 
choosing newer targets for gene therapy. 
2. Known targets for gene therapy 
The general aim of gene therapy is to introduce a well-defined DNA sequence into specific 
cells. Almost any disease can be targeted with gene therapy by replacing defective genes or 
imparting a new function. In fact, 85% of clinical trials in gene therapy have been conducted 
for cancer, cardiovascular diseases and for inherited monogenic diseases. In addition, 6.5% 
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of clinical trials have been conducted for infectious diseases (mainly HIV). Cancer, 
cardiovascular diseases and HIV are ideal gene therapy targets because of their enormous 
prevalence and the associated fatal consequences of these diseases, whereas monogenic 
disorders reflect the original idea of gene therapy which is replacement of a defective gene. 
Gene therapy offers a unique opportunity to cure patients with monogenic disorders. One 
third of clinical trials for monogenic disorders are for cystic fibrosis while about 20% are for 
SCID (Edelstein et al. 2004). This section highlights the advantages of gene therapy for 
multifactorial diseases such as cancer, vascular diseases, and HIV and describes the utility of 
gene therapy for monogenic diseases such as cystic fibrosis, SCID and ǃ-thalassemia. 
2.1 Cancer 
Cancer was responsible for 7.6 million deaths in 2008 (WHO 2011) and is the largest target 
for gene therapy clinical trials. The complexity of cancer may make it difficult to bring a 
product to the market due to the number of genes involved compared to monogenetic 
disorders. However, gene therapeutics are not designed to correct these mutations by 
adding an enormous amount of DNA to the cells. Instead, they target critical proteins 
involved in signaling cascades such as the tumor suppressor p53. For example, the first gene 
therapy product was GendicineTM, an adenovirus containing the tumor suppressor p53. 
The tumor suppressor p53 is mutated in 40% of many types of cancers, and malfunction of 
p53 is the major contributor for chemotherapy resistance (Goh et al. 2011). Apoptosis can be 
triggered by transcriptionally active p53 in the nucleus (Taha et al. 2004) as well as by p53-
mediated transcriptionally independent mechanisms in the mitochondria (Vaseva et al. 
2009). Various animal studies have shown that p53 induces apoptosis even in advanced 
tumors such as lymphoma and hepatocellular carcinoma (Ventura et al. 2007; Palacios & 
Moll 2006; Xue et al. 2007).  
The first p53 based gene therapy in humans was conducted in 1996. This trial used a 
retroviral vector containing wild type p53 with an actin promoter for the treatment of non-
small cell lung carcinoma. In this study three patients showed tumor regression and three 
other patients showed tumor growth stabilization (Roth et al. 1996). China was the first 
country which approved a p53 adenovirus for gene therapy, GendicineTM SiBiono, in 
combination with radiotherapy for head and neck squamous cell cancer in 2004 (Shi & 
Zheng 2009). GendicineTM is a recombinant serotype 5 adenovirus with the E1 region 
replaced by the p53 expressing cassette (with a Rous sarcoma virus promoter). The 
adenovirus particles infect tumor target cells carrying therapeutic p53 (Peng 2005). Clinical 
trials for GendicineTM showed that in combination with radiation therapy it caused partial 
or complete tumor regression (Peng 2005; Xin 2006). There were also some clinical trials for 
GendicineTM in advanced liver cancer, lung cancer and other advanced solid tumors (Peng 
2005). It should be kept in mind that China’s State Food and Drug Administration (SFDA) 
has different standards for the approval of a cancer drug compared to the U.S. FDA and the 
European Medicine Agency (EMA). GendicineTM was approved in China on the basis of 
tumor shrinkage. The U.S. FDA and the EMA require novel cancer drugs to extend the 
lifetime of the treated patients (Guo & Xin 2006).  
Another p53 product is OncorineTM from Shanghai SunwayBiotech, an oncolytic virus. 
OncorineTM was approved for the treatment of head and neck cancer in China in 2006 (Yu & 
Fang 2007). It is a replicative adenovirus 2/adenovirus 5 hybrid with deletion in E1B55K 
and E3B (Raty et al. 2008). This oncolytic virus was expected to infect and lyse cancer cells 
only and not affect normal cells (Guo et al. 2008). Even though clinical studies showed that it 
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was not specific for cancer cells, it did, however, kill tumor cells preferentially (Garber 2006). 
Phase I/II trials showed little dose-limiting toxicity (Lockley et al. 2006) and the 
combination of OncorineTM with chemotherapy showed greater tumor shrinkage in patients 
with head and neck cancer, compared to chemotherapy alone. It should be kept in mind that 
like GendicineTM, OncorineTM was also approved by the SFDA based on objective response 
rate, not on survival (Garber 2006). Nevertheless, all the available data concerning p53 and 
its proven function as tumor suppressor qualifies it as an adjuvant treatment with 
radiotherapy or chemotherapy.  
Another approach to cancer gene therapy is gene-directed enzyme prodrug therapy 
(GDEPT).  GDEPT transfers an activating transgene into tumor cells followed by systemic 
treatment with a non-toxic drug which becomes activated only in cells expressing the 
transgene. CereproR is an adenovirus containing a herpes simplex type-1 thymidine kinase 
transgene under the cytomegalovirus promoter. CereproR is under phase I, II and III clinical 
trials in Europe for malignant glioma, a fatal form of brain cancer. In these clinical trials 
CereproR was injected multiple times into healthy brain tissues of patients following 
surgical removal of the solid tumor mass. Then the patients were treated with the prodrug 
ganciclovir, which is converted to its toxic form, deoxyguanosine, by thymidine kinase. This 
toxic metabolite affects newly dividing cells, thus it prevents new tumors from growing. In 
phase I and II trials, patients given CereproR showed a significant increase in survival. 
However, after phase III studies, the EMA rejected the marketing application for CereproR 
due to inadequate efficacy (van Putten et al. 2010; Cerepro 2009; Mitchell 2010; Raty et al. 
2008). Despite this particular failure, systemic side effects are avoided with the GDEPT 
concept. The general goal of GDEPT is the improvement of chemotherapy in terms of safety 
and efficiency using concomitant gene therapy (Edelstein et al. 2004).  
2.2 Cardiovascular diseases 
Cardiovascular diseases (CVD) encompass disorders of the heart and blood vessels and 
include hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular 
disease, heart failure, rheumatic heart disease, congenital heart disease and 
cardiomyopathies (Chiuve et al. 2006). Cardiovascular diseases are the largest health 
problem worldwide, claiming 17.1 million lives per year. Despite the complexity of 
cardiovascular disease, there is great potential for gene therapy especially in ischemia, 
angiogenesis, hypertension and hypercholesterolemia. Currently there is no gene therapy 
product on the market for CVD. Nevertheless, several clinical trials have been conducted 
(Edelstein et al. 2004; Edelstein et al. 2007). Most gene therapies for CVD aim to increase 
angiogenesis which is a mechanism to overcome ischemia. Ischemia is a condition in which 
the flow of blood is restricted to parts of the body. The response of the body is to form new 
blood vessels around the blockage, called angiogenesis, and is triggered by angiogenic 
proteins such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 
and hepatocyte growth factor (HGF) (Abo-Auda & Benza 2003; Kass et al. 1992). The goal of 
introducing genes coding for these growth factors is to increase the local concentration of 
these factors to stimulate angiogenesis (Edelstein et al. 2004). Two companies are conducting 
phase III clinical trials using FGF. Bayer Schering Pharm AG has developed alferminogene 
tadenovec, which is a replication-deficient human adenovirus serotype 5 which encodes 
human FGF4. Since myocardial ischemia is linked to coronary artery disease, the therapeutic 
goal is to improve the reperfusion of ischemic myocardium. Phase IIb/III clinical trials 
showed that it is well-tolerated; a phase III trial is ongoing to prove its efficacy (Flynn & 
www.intechopen.com
 
Targets in Gene Therapy 
 
6 
O'Brien 2008; CardioVascular BioTherapeutics). Sanofi-Aventis is developing a FGF gene 
therapy product called riferminogene pecaplasmide or NV1FGF (Riferminogene 
pecaplasmide  2010). It is a novel pCOR (conditional origin of replication) plasmid-based 
gene delivery system (Maulik 2009). NV1FGF is injected into muscle cells, and expresses 
FGF-1. The therapeutic goal is to treat chronic/critical limb ischemia since limb ischemia is 
linked to peripheral artery disease (Baumgartner et al. 2009). Phase III clinical trials are 
ongoing in 32 countries (Riferminogene pecaplasmide  2010). 
Another gene therapy approach to treat limb ischemia uses HGF. There are several animal 
studies showing that HGF can trigger formation of new blood vessels (Shigematsu et al. 
2010). The injection of the naked HGF gene is well-tolerated as shown in the first clinical 
trial conducted in Japan (Morishita et al. 2004). Another clinical trial in the U.S. showed that 
HGF injection increased tissue perfusion compared to placebo (Powell et al. 2008). Lastly, 
there is also a clinical trial to prove efficacy of HGF gene therapy, using reduction of ulcer 
size and decrease in rest pain (pain occurring during sleep) as objectives (Shigematsu et al. 
2010). 
2.3 HIV 
The human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome 
(AIDS), a severe disease characterized by profound negative effects on the immune system 
leading to life-threatening opportunistic infections. Although antiretroviral drugs have 
decreased the morbidity and mortality of HIV infected patients, currently there is no cure. 
However, new developments in gene therapy have focused on introducing genes encoding 
RNA or proteins which are capable of interfering with intracellular replication of HIV, so-
called intracellular immunization. So far, the approaches range from protein-based 
strategies such as fusion inhibitors or zinc finger nucleases to RNA-based approaches such 
as ribozymes, antisense or short hairpin RNA. Currently, a promising target is the 
chemokine receptor 5 (CCR5) which is needed for fusion of HIV with immune cells. Studies 
have shown that patients with mutated CCR5 have a higher long-term survival and slower 
progression of the disease. A homozygous defect in the CCR5 gene, a Δ32 deletion, resulting 
in a lack of functional CCR5 protein and confers resistance to HIV infection (Liu et al. 1996). 
An allogeneic stem-cell transplantation of CCR5 defective cells in a patient with HIV 
infection and acute myeloid leukemia resulted in both a negative HIV plasma viral load and 
no detection of HIV proviral DNA for more than 3.5 years after treatment (without the use 
of antiviral drugs). This result has been classified as a cure of HIV (Kitchen et al. 2011, and 
references therein; Symonds et al. 2010, and references therein). 
2.4 Monogenic diseases 
Monogenic diseases are prime targets for gene therapy due to their simple single gene 
mutations. Their disease causing mechanisms are easier to elucidate which is advantageous 
for choosing a target for gene therapy. In addition, the execution of therapy is more 
straightforward, since it is easier to transfer single genes into cells instead of several genes. 
Other important factors are the location and the type of cell in which the gene has to be 
transferred. Is the cell reachable with existing delivery systems? Is the cell already 
differentiated or is it a still dividing stem cell? Does gene transfer need to be repeated or is a 
one-time transfer sufficient? All these questions have to be considered in order to choose the 
right target for gene therapy, and it must be noted that not every disease caused by single 
gene mutations can be targeted. Three examples of well-studied diseases and attempts to 
treat these diseases using gene therapy will be discussed. 
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2.4.1 Cystic fibrosis 
Cystic fibrosis (CF) is a complex inherited disease affecting the lungs and digestive system. 
The cause of this disease is a defect in the cystic fibrosis transmembrane conductance 
regulator (CFTR), which is a chloride channel on the apical membrane of respiratory 
epithelia. This leads to reduced Cl- and increased Na+ permeability (Boucher et al. 1988). CF 
is caused by several different mutations in the CFTR gene located on chromosome 7 
(Knowlton et al. 1985). Of the hundreds of mutations that cause CF, the most common 
mutation, which occurs in approximately 70% of all cases, is the deletion of a phenylalanine 
residue at amino acid position 508 (ΔF508) (Kerem et al. 1989). CF results in decreased 
production of pancreatic enzymes leading to malnutrition, and also blocks the lung with 
unusually viscous mucus leading to life-threatening infections (Cystic Fibrosis Foundation; 
Wood 1997). It is possible to treat symptoms of CF to improve quality of life but there is no 
current cure for this disease. Mainstays for symptomatic treatment include enzymatic 
therapies (pancreatic enzymes and DNAse I) (McPhail et al. 2008), airway clearance and 
hypertonic saline for improved lung function, use of drugs that enhance Cl- secretion in 
airway epithelium (Cloutier et al. 1990) and anti-inflammatories involving ibuprofen or 
corticosteroids (Flume et al. 2010, and references therein). Despite a clear understanding of 
genetic links, gene therapy is not yet a standard treatment for CF, as recent attempts to cure 
patients with CF have not been successful. Moss et al. showed improvement in pulmonary 
function in a phase II clinical trial with 42 CF patients, of whom 20 received at least one dose 
of aerosolized adeno-associated serotype 2 virus carrying the CFTR gene. A significant 
enhancement in FEV1 (forced expiratory volume per second) was noted after 30 days 
compared to placebo. Furthermore, this study showed no adverse events demonstrating the 
safety of adeno-associated vectors (Moss et al. 2004). However, when this same group 
performed a second, larger phase IIb trial with 102 subjects, there was no significant 
improvement in FEV1 seen after 30 days compared with placebo (Moss et al. 2007). 
Expression of CFTR was noted in airway epithelium of 7 individuals with CF after the first 
administration but the effect lasted only 30 days. The second administration showed 
decreased expression. Finally, at the third administration, the expression fell to zero (Harvey 
et al. 1999). In conclusion, there is some indication that gene therapy could be used to cure 
CF, but no method has shown to be universally applicable. Further research is needed to 
find the right vector with repeatable administration and subsequent high expression while 
simultaneously being safe. Gene therapy for CF targets epithelial cells which have a limited 
life span and do not divide. Because of that, the gene has to be transferred repeatedly into 
new growing cells, which is problematic since repeated transfections have been ineffective.   
2.4.2 Severe combined immunodeficiency 
Severe combined immunodeficiency (SCID) is a rare, fatal syndrome with an incidence of 
24.3 cases per million live births (Ryser et al. 1988). The disease is characterized clinically by 
defects in humoral and cellular immunity due to profound deficiencies of T-and B-cell 
function, and if left untreated usually leads to death in infancy (Buckley et al. 1997). 
Mutations leading to SCID appear in various genes including Jak-3, adenosine deaminase, 
IL-7 receptor (Puel et al. 1998), tyrosine phosphatase CD45 (Kung et al. 2000), the 
interleukin-2 (IL-2) receptor Ǆ chain (IL2-RǄ), the Artemis gene (Kobayashi et al. 2003) and 
recombinase activating genes 1 or 2 (Schwarz et al. 1996; Buckley et al. 1997, and references 
therein). The most frequently diagnosed form of SCID is X-SCID, which is characterized by 
a mutation in the IL2-RǄ gene located on the X chromosome. This disease shows a male 
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predominance, with a mean age of diagnosis of 6.6 months. The IL2-RǄ chain is a critical 
component of many cytokine receptors including those for IL-2, -4, -7, -9, -15 and 21, where 
defects may result in greatly decreased numbers of T and NK cells. The number of B cells is 
generally normal but their activity is abnormal (Buckley et al. 1997). After maternal 
antibodies have vanished, the extreme susceptibility to infection due to opportunistic 
microbes, persistent diarrhea and failure to thrive usually lead to death in the first year of 
life unless immunologic reconstruction can be achieved. 
Hematopoietic stem cell transplantation is the standard of care for all genetic types of SCID 
with a survival rate of nearly 80% with HLA-identical parental marrow (Antoine et al. 2003). 
Even with a matched donor, stem cell transplantation may lead to long-term clinical 
complications (De Ravin & Malech 2009). Thus, other treatments for SCID are needed. An ex 
vivo gene therapy trial with two X-SCID patients, aged 8 and 11 months, demonstrated that 
gene therapy has curative potential. Administration of a retroviral vector containing the 
correct IL2-RǄ gene resulted in T cell counts similar to that of age-matched controls after 105 
days. Furthermore, the immune system responded to tetanus toxin and polioviruses within 
the normal range after primary vaccination. Both patients later showed normal growth and 
psychomotor development (Cavazzana-Calvo et al. 2000). Other studies confirmed these 
results (Hacein-Bey-Abina et al. 2002; Thrasher et al. 2005). A separate study of gene therapy 
for X-SCID with children aged 2.5, 4 and 8 years old showed mixed results. Only the 
youngest patient experienced benefit from the treatment (Chinen et al. 2007). Another trial 
with two patients, aged 15 and 20 years old also failed (Thrasher et al. 2005). Despite the 
variable outcome from these studies, gene therapy may still potentially cure X-SCID and 
other SCIDs, in particular for younger patients. It is already possible to cure newborn 
children with this modern technique, if traditional methods like BMT fail. If the safety of 
gene therapy vectors can be improved to lower the risk of insertional mutagenesis, gene 
therapy will likely become first-line therapy for to the treatment of X-SCID. In contrast to 
CF, the presence of accessible stem cells in which the functional gene could be transferred 
would allow continuous expression of this gene, making X-SCID a good candidate for gene 
therapy. 
2.4.3 β–thalassemia 
ǃ–thalassemia syndromes are a group of inherited blood disorders. Thalassemia major is 
the only transfusion-dependent type of ǃ-thalassemia and manifests itself clinically 
between 6 and 24 months of life by paleness and failure to thrive. It is marked by reduced 
(ǃ+) or absent (ǃ0) beta globin chain synthesis caused by several different single gene 
mutations, resulting in reduced hemoglobin in red blood cells (Weatherall 1976). If left 
untreated, this disease results in growth retardation, pallor, jaundice, poorly developed 
musculature, skeletal changes and other consequences leading to death during infancy 
(Cao & Galanello 2010). Blood transfusion is the current standard therapy for ǃ–
thalassamia and aims to correct the anemia from reduced hemoglobin (Cao & Galanello 
2010). This treatment, however, carries the risk of infection from blood borne diseases 
such as HIV and hepatitis and as well as the serious side effect of transfusional iron 
overload which is fatal if untreated. Currently, BMT offers the best chance for curing ǃ-
thalassemia in both in children and adults if a HLA identical donor is found, but is limited 
by complications like graft-versus-host disease or finding suitable donors (Lucarelli & 
Gaziev 2008). 
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Gene therapy of human ǃ-thalassemia is still in its infancy and requires the development of 
efficient, safe and high level gene transfer into target hematopoietic stem cells. It also 
requires regulation of erythroid lineage-specific expression and therapeutic levels of ǃ-
globin expression (Malik & Arumugam 2005). Meeting these requirements may be difficult, 
but a successful gene therapy trial was achieved in 2007 when an 18 year-old patient was 
effectively treated using a ǃ-globin-expressing lentiviral vector. The vector was transfected 
ex vivo into harvested CD34+ cells and then transplanted back into the patient’s bone 
marrow. The patient, who had no HLA-matched donors (making BMT impossible), was 
treated with high dose chemotherapy with intravenous busulfan to eliminate defective 
hematopoetic stem cells (HSC) prior to transplantation. This step was critical for the success 
of this treatment to prevent the defective HSC from diluting the corrected HSC. Three years 
post-transplant this patient no longer required blood transfusions and showed stable 
hemoglobin levels. However, mild anemia, compensatory expansion of red-blood-cell 
precursors in bone marrow, and other safety concerns have been raised (including 
development of cancers) (Cavazzana-Calvo et al. 2010). Although the long-term prognosis 
and outcome of gene therapy for ǃ-thalassemia is currently unclear, it still has the same 
advantage of the presence of accessible stem cells as X-SCID. With this in mind, targeting 
stem cells may be more successful than differentiated cells, and may be sufficient to cure the 
disease. 
3. Identifying novel targets for gene therapy 
Before targeting a disease with gene therapy, the genetic basis of that disease should be 
identified. Strategies for finding disease genes have greatly improved in the last few years 
due to the Human Genome Project and the Hap Map Project. The Hap Map Project 
identifies and catalogs genetic similarities and differences in humans (Human Genome 
Project; The International Hap Map Consortium 2003) and supplies computerized databases 
to search through and identify new gene therapy targets (Hap Map Project 2003). To find 
genes the two most common options are candidate-gene studies and genome-wide studies. 
Candidate-gene association studies are based on prior biological knowledge of gene 
function or on significant findings in linkage studies. This method is based on a single 
polymorphism and haplotypes and compares allele or haplotype frequencies between the 
case and the control group. Genome-wide studies can be divided into linkage mapping and 
genome-wide association studies. Genetic linkage mapping studies are used to discover and 
identify new genes by using genetic and phenotypic data from families. The analysis is 
conducted without any prior knowledge about genetic basis of disease. Linkage analysis 
functions by comparing genotype polymorphic markers at known locations in the genome. 
Genome-wide association studies are the most recent technology. They search the whole 
genome for single nucleotide polymorphisms (SNPs). Each study can look at hundreds or 
thousands of SNPs at the same time (for an excellent review see (Hirschhorn & Daly 2005)). 
The results are plotted into biostatistics algorithms (Nakamura 2009; Hirschhorn & Daly 
2005). The proteins identified by genomic methods can be further characterized by standard 
molecular and biochemical assays. In addition, protein targets have been identified by 
individual labs using standard molecular and biochemical methods without a priori use of 
genomic information. With the growing understanding of genes associated with many 
diseases the future for new gene therapeutics shows promise.  
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Fig. 1. Finding Novel Gene Therapy Targets. Integration of standard and modern 
technologies for disease-causing targets for gene therapy. 
3.1 Methods to find gene therapy targets 
Microarrays lay the groundwork for the methods mentioned above. The two most important 
advantages of microarrays are their small scale (multi-well plate formats) and ability to 
detect thousands of different immobilized genes simultaneously (Duggan et al. 1999; 
Siegmund et al. 2003; NCBI 2007). There are three types of microarray technologies: 
comparative genomic hybridization, expression analysis and mutation/polymorphism 
analysis, though the principle remains the same for all. First, the DNA chip corresponding 
to the DNA of interest is selected. Then, isolated messenger RNA (mRNA) is used as a 
template to generate complementary DNA (cDNA), with a fluorescent tag. This mixture is 
incubated with the DNA chip. During this incubation, tagged cDNA can specifically bind to 
the complementary DNA template on the chip. Afterwards, the hybridized cDNA can be 
detected with lasers specific to different fluorophores followed by analysis using 
computational methods (NCBI 2007). 
The Human Genome Project and the HapMap project have provided the foundation for 
candidate gene and genome-wide studies. Using these methods may allow us to draw 
conclusions between gene abnormalities and diseases. For example, many different studies 
have been conducted to determine the genes associated with cardiovascular diseases. In fact 
many CVDs are linked to mutated genes. For example, there is evidence based on genetic 
linkage analysis that chromosomes 1, 2, 3, 13, 14, 16 and X are involved in myocardial 
infarction, which is the major killer world-wide. Additionally, myocardial infarction and 
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stroke are associated with mutations in chromosome 13q12-13 containing the ALOX5AP 
gene encoding arachidonate 5-lipoxygenase-activating protein. Furthermore, high LDL, low 
HDL and high triglycerides values are high risk factors for cardiovascular disease, with 
linkage results located in all autosomes except for 2 and 14 (Arnett et al. 2007, and references 
therein). 
Finding disease-causing genes may not only help to better understand the pathophysiology 
of the disease, but may improve the diagnosis of the disease by discovery of disease-specific 
marker genes. Importantly, identification of disease-causing genes will lead to new targets 
for improved therapeutics. Genome-wide association studies which scan markers across the 
entire genome can find single mutations causing monogenic disorders as well as different 
mutations in several genes, which may lead to more gene therapy-based cures for these 
diseases.  
3.2 Hub proteins 
Genomic sequencing information, microarrays, and molecular/biochemical assays are tools 
that can help determine which proteins are responsible for disease. This information can be 
analyzed to identify hub proteins involved in disease progression. Hub proteins are key 
proteins that signal to multiple other proteins in transduction cascades. They are highly 
connected to other proteins with multiple interaction partners. Hub proteins bind with 
several distinct binding sites to other proteins. Studying the binding interface of cancer-
related proteins maybe useful for better understanding of cellular function and biological 
processes (Keskin & Nussinov 2007; Kim et al. 2006).  
3.2.1 Tumor suppressor hub proteins   
3.2.1.1 p53 
The tumor suppressor p53 is an example of a hub protein involved in cancer which loses the 
ability to bind different other proteins due to mutations (Shiraishi et al. 2004). It induces 
transactivation of target genes which are responsible for cell cycle arrest, DNA repair and 
apoptosis. p53 is mutated in 40% of cancers (Goh et al. 2010). In normal, healthy cells p53 is 
rapidly degraded via the MDM2 pathway, but when stress signals occur, p53 accumulates 
dramatically in the cell, allowing it to accomplish its apoptotic functions. p53 stimulates 
multiple signaling mechanisms which lead to apoptosis: the extrinsic pathway through 
death receptors and the intrinsic pathway through the mitochondria (Haupt et al. 2003). As 
a transcription factor it binds to p53-responsive genes, and the expressed proteins trigger 
apoptosis, G1 arrest, as well as DNA repair through different mechanisms. In addition, p53 
translocates to the mitochondria and induces a rapid apoptotic response (Erster et al. 2004; 
Haupt et al. 2003). Consequently, p53 fulfills the requirements for an ideal hub protein for 
gene therapy. Indeed, p53 adenovirus has been used for cancer therapy, and was the first 
gene therapeutic on the market.  
3.2.1.2 BRCA1 and BRCA2 
Breast cancer susceptibility protein (BRCA)1 and BRCA2 are highly associated with breast 
and ovarian cancer. The lifetime risk of developing breast cancer for a person carrying 
mutations in both genes is 82%; mutations in BRCA1 account for 52% and BRCA2 for 23% of 
all cases. Furthermore, the risk for ovarian cancer is dramatically increased due to mutations 
in BRCA1 and/or BRCA2. Thus, it is important to identify patients with a probability of 
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having mutations in these proteins. BRCA1 and BRCA2 regulate cell cycle progression, 
DNA repair and gene transcription (Metcalfe et al. 2005).  Their export into the cytoplasm is 
associated with apoptosis. In cooperation with cellular partner BARD1 (BRCA1-associated 
RING domain protein), BRCA1 is able to enter the nucleus and accomplish its role in DNA 
repair, centrosome regulation and RNA processing (Henderson 2005; Rodriguez et al. 2004). 
When the sensitive balance between BARD1 and BRCA1 is defective due to cancer-
promoting mutations in both, they remain as a dimer which results in nuclear 
compartmentalization leading to dramatic reduction of their apoptotic activity (Davis et al. 
2007; Rodriguez et al. 2004). Silencing BRCA1 expression using RNA-mediated interference, 
results in increased cytoplasmic levels of BARD1 and causes apoptosis in breast cancer cell 
lines (Rodriguez et al. 2004). BARD1 translocates to the mitochondria and causes 
oligomerization of Bax which results in apoptosis (Tembe & Henderson 2007). Therefore, 
targeting BRCA1 is a viable gene therapy-based approach.  
3.2.2 Hub proteins that promote cancer 
3.2.2.1 Survivin 
In addition to adding back hub tumor suppressors for gene therapy, oncogenic hub proteins 
can be blocked as well. The oncogene survivin is nearly universally expressed in various 
types of cancer and is almost undetectable in most adult tissue. Survivin is a unique member 
of the inhibitor of apoptosis protein (IAP) family and plays a major role as a mitotic 
regulator (Altieri 2001, and references therein). It is involved in multiple cancer-promoting 
mechanisms, particularly inhibition of apoptosis. Various parallel pathways, such as 
intervention in mitochondrial function, inhibition of caspases, and influence on gene 
expression are responsible for survivin’s anti-apoptotic function (Altieri 2008, and references 
therein). For example,  survivin and its binding partners act to prevent caspase activation; 
activated caspase 9 is required to activate effector caspase 3 and caspase 7, which execute 
mitochondrial-induced apoptosis (Li & Yuan 2008). Also, a splice variant of survivin, 
survivin ΔEx-3, translocates to the mitochondria where it interacts with proteins from the 
Bcl-2 family. These proteins are inhibitors of permeabilization of the mitochondrial outer 
membrane which is essential for cytochrome c release. Stabilization of Bcl-2 proteins 
prevents cytochrome c release, thus resulting in the inhibition of caspase 9 and caspase 3 
(Altieri 2008, and references therein). Furthermore, survivin’s role as a mitotic regulator is 
related to its inhibition of apoptosis. Survivin expression is upregulated at the G2/M phase 
to localize to the mitotic apparatus and is downregulated in interphase via ubiquitin-
dependent destruction (Li, Ambrosini, et al. 1998; Zhao et al. 2000). High survivin 
expression was detected in various types of cancers including breast, lung, colon, stomach, 
esophagus, pancreas, uterus, ovary and liver (Altieri 2008, and references therein). Dramatic 
overexpression of survivin correlates with more aggressive and invasive clinical phenotypes 
which means a poor prognosis compared to survivin-negative tumors, an increased rate of 
recurrence and chemotherapy resistance (Kato et al. 2001; Grossman & Altieri 2001). The 
differential expression and function of survivin make it an excellent target for cancer 
therapy (Altieri 2003). There are many gene-based strategies to inhibit survivin in cancer 
cells, with some in phase I and II clinical trials. One gene-based method uses survivin 
antisense oligonucleotides to prevent expression in cancer cells. Two phase II trials and one 
phase I trial by Eli Lilly and Co. are ongoing for relapsed or refractory acute myeloid 
leukemia, hormone refractory prostate cancer and advanced hepatocellular carcinoma (Ryan 
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et al. 2009). Furthermore, Alteri et al. created a replication-deficient adenovirus containing a 
dominant negative survivin mutant where threonine 34 is mutated to alanine. This mutation 
abrogates phosphorylation of threonine which impairs survivin’s ability act as a mitotic 
regulator, as only phosphorylated survivin is able to localize to the mitotic apparatus 
(O'Connor et al. 2000). Injection of adenovirus containing survivin mutant triggers apoptosis 
by cytochrome c release which leads to caspase 3 activation. Alteri et al. demonstrated in 
several cancer cell lines that this mutant causes apoptosis and confirmed these results in 
three xenograft breast cancer mice models. Interestingly, this survivin mutant was not able 
to cause apoptosis in proliferating normal human cells (Mesri et al. 2001). 
3.2.2.2 Ras 
The RAS supergene family is divided into six subfamilies RAS, RHO, RAB, ARF, RAN and 
RAD which code for more than 50 structurally related proteins. Their main function is to 
transmit signals from cell-surface receptors to the cell interior. All proteins have a guanosine 
triphosphate (GTP) binding motif in common and participate in signaling cascades. The 
RAS subfamily functions in proliferation and differentiation which makes it a prime target 
for anti-cancer therapy. The localization of Ras on the cell membrane, and binding to GTP 
are essential for its function. When Ras binds to GTP, it initiates the signaling pathway for 
cell proliferation and differentiation. However, when Ras-GTP is hydrolyzed to Ras-GDP by 
GTPase-activating proteins (GAPs), it is unable to activate its signal transduction pathway. 
This sensitive regulation process is out of balance in cancer cells due to different mutations 
in the RAS gene. Most of these mutations occur in the Ras gene itself and in the regulatory 
proteins of the Ras pathway. These mutations cause Ras to stay in the active Ras-GTP form 
and prevent conversion into the inactive Ras-GDP form. Mutated Ras protein is hyperactive 
and triggers cancer development. Hyperactive Ras is associated with different types of solid 
tumors such as pancreatic, cervical, thyroid, colon, skin, and lung tumors as well as with 
hematopoietic malignancies such as chronic myelomonocytic leukemia, acute myelogenous 
leukemia and multiple myeloma to list a few. Ras is an excellent gene therapy target due to 
its involvement in various cancers (Beaupre & Kurzrock 1999, and references therein). 
Recently it has been shown that knocking out Ras with an anti-Ras mRNA plasmid-
mediated short-hairpin RNA in combination with clinical drug vincristine resulted in 
inhibition of the growth of human hepatoma HepG2 in vivo (Sun et al. 2009). This illustrates 
once again that the combination of gene therapy with standard chemotherapy is a promising 
approach for treatment of cancer.  
3.2.2.3 AKT 
AKT, a serine/threonine kinase, plays an essential role in oncogenesis. The AKT family 
consists of three cellular homologues AKT1, AKT2 and AKT3. The encoded proteins have a 
similar structure consisting of an amino-terminal pleckstrin homology domain, a short ǂ-
helical linker and a carboxy-terminal kinase domain. Tissues have different expression 
levels of the three homologues AKT1, AKT2 and AKT3, which is why it is not surprising 
that the three different variants of AKT are overexpressed in different types of cancers. For 
example, AKT1 is overexpressed in gastric cancer and is associated with poor prognosis in 
breast and prostate cancer; AKT2 is overexpressed in ovarian and pancreatic cancer. AKT3 
is overexpressed in estrogen receptor-deficient breast cancer and in androgen-insensitive 
prostate cancer which implies that AKT3 contributes to aggressive steroid hormone-
insensitive cancer. AKT acquires growth signal autonomy and inhibits apoptosis in cancer 
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cells. It promotes cell survival through its phosphorylation of MDM2, which enhances 
nuclear accumulation of MDM2. MDM2 inhibits the transcriptional activity of p53 and 
promotes its degradation by the proteasome (Testa & Bellacosa 2001). AKT gene therapy has 
been conducted with an aerosol delivery system consisting of nano-sized glucosylated 
polyethylenimine (GPEI). It has been shown that this aerosol is capable of delivering AKT 
wild-type and kinase deficient genes into the lung of mice (Tehrani et al. 2007). Dominant 
negative alleles of AKT directly injected into lung carcinoma cells have also been shown to 
block cell survival and proliferation (Li, Simpson, et al. 1998). 
3.3 Protein-protein interactions 
A protein dimer or oligomer is a macromolecular structure formed by two (dimer) or 
several (oligomer) proteins of either same origin (homo-oligomers) or different origins 
(hetero-oligomers). For several proteins the formation of oligomers or dimers is essential in 
order to form functional systems. Both Bcr-Abl and p53 proteins function in the homo-
oligomeric form. On the other hand, hemoglobin forms hetero-oligomers consisting of two ǂ 
and two ǃ subunits to form a functional structure. If one of these subunits is defective or 
missing, the protein cannot master its tasks leading to diseases such as the previously 
described ǃ-thalassemia. Mutations in the oligomerization domain can lead to loss of 
function. Dimer or oligomer formation is governed by non-covalent interactions, including 
salt bridges, hydrogen bonds and hydrophobic interactions. A common structural motif for 
dimerization is a coiled coil consisting of usually two to five ǂ-helices that wind around one 
another like strands of a rope, meshed together like “knobs-into-holes.” They contain a 
characteristic seven-residue sequence repeat (Mason & Arndt 2004; Crick 1952). Coiled coil 
motifs play an important role in the function of several different proteins ranging from 
transcription factors such as Jun and Fos which are responsible for cell growth and 
proliferation (Glover & Harrison 1995) to the oncoprotein Bcr-Abl which leads to cancer 
(McWhirter et al. 1993). A subgroup of the coiled coil motif is represented by the “leucine 
zipper”, an unusually long ǂ-helix with protruding leucine residues in periodic repetition. 
The leucine residues from one peptide interact with leucine residues from a second peptide, 
forming a molecular zipper (Landschulz et al. 1988). Another important dimerization 
interface for proteins is the helix-loop-helix (HLH) motif. Characterized by two ǂ-helices 
connected by a short loop, this structure is highly conserved in many diverse organisms. 
Proteins containing this structure are transcription factors that are only functional as homo- 
or hetero-dimers (Murre et al. 1994, and references therein). Important HLH family 
members are myc proteins which play an essential role in cell proliferation, differentiation, 
cell growth, and apoptosis, but are also involved in development of numerous kinds of 
cancer (Vita & Henriksson 2006). Finally, another interaction motif is the zinc finger motif, 
containing several subgroups such as C2H2, Gag knuckle, treble clef, zinc ribbon, 
Zn2/Cys6, TAZ2 domain like, zinc binding loops and metallothionein (Krishna et al. 2003). 
The C2H2 zinc finger represents the most prevalent motif and contains a zinc ion 
coordinated by cysteines and histidines (Wolfe et al. 2000). Although most C2H2 fingers 
apparently contribute to protein-DNA or protein-RNA interactions, examples for protein-
protein interactions also exist. One example is Ikaros, a transcription factor participating in 
gene silencing and activation in hematopoietic cells. In this protein, dimerization is 
important for its activity and affinity to DNA (McCarty et al. 2003, and references therein). 
In addition, more complex oligomerization structures exist. For example, p53 forms a dimer 
with an antiparallel ǃ-sheet and an antiparallel helix-helix interface. Two dimers associate as 
a parallel helix-helix to form a tetramer (Jeffrey et al. 1995). 
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Gene therapy may be used to enhance or inhibit dimerization interfaces. Currently, small 
molecule drugs are unable to re-establish the ability of proteins to form dimers with the aim 
of restoring their natural function. In contrast, gene therapy can supply dimerization-
capable and functional proteins. On the other hand, if the formation of a dimer is unwanted, 
it is possible to disrupt the dimerization interface of a disease-causing protein by 
introducing proteins into the cell which compete for dimerization. Normal dimerization of 
the disease-causing protein is then blocked, hence stopping the disease. 
3.3.1 Homo-oligomerization for apoptotic activity 
The classic example of a protein that is only functional as a homo-oligomer is p53. The 
protein p53 is 393 amino acids long and contains a transactivation domain (amino acids 1-
43) and a proline-rich domain (amino acids 61-94), a DNA-binding domain (amino acids 
110-286), a tetramerization domain (amino acids 326-355) and a regulatory region (amino 
acids 363-393) (Chene 2001). As already mentioned, mutations of TP53, the gene encoding 
for p53, occur in a large proportion of human cancers. Some of these mutations may prevent 
the formation of tetramers, which lead to loss of p53 function (Vogelstein et al. 2000). Not 
only does the site-specific binding to DNA depend on oligomerization , but so do a number 
of post-translational modifications of p53 which are believed to be important regulators of 
p53 activity (Chene 2001, and references therein). Reintroducing tetramerization-capable 
p53 using gene therapy may allow treatment of cancers which are caused by mutations in 
this region of TP53. So far 49 mutations in the tetramerization domain of p53 have been 
described, even though not all mutations prevent dimerization or tetramerization. Most of 
these occurring mutants still form tetrameric structures like wild-type p53 but with reduced 
stability (Kamada et al. 2011).  
Another example where protein oligomerization yields functionality occurs with DJ-1. This 
protein bears cytoprotective functions within cells and protects neurons from stressful 
stimulants. A L166P mutation in the DJ-1 gene may prevent its ability to homodimerize, and 
it has been speculated that this can lead to neurodegeneration in autosomal recessive early 
onset Parkinsonism (Gorner et al. 2007, and references therein). Re-introduction of 
dimerization-capable DJ-1 with gene therapy is therefore a possible treatment option. 
3.3.2 Disruption of disease-causing homo-oligomerization  
Like p53, Bcr-Abl is also a protein that functions as a homo-oligomer (dimer of dimers). 
However, Bcr-Abl derives oncogenic function rather than tumor suppression from 
oligomerization. Bcr-Abl results from the fusion of the breakpoint cluster region (Bcr) gene 
on chromosome 22 and the Abelson leukemia oncogene (Abl) on chromosome 9. This results 
in an abnormal shortened chromosome called the Philadelphia chromosome. Bcr-Abl 
functions as an oncoprotein leading to increased cell proliferation and inhibition of 
apoptosis due to the constitutive activation of tyrosine kinase activity and causes 95% of all 
cases of chronic myeloid leukemia (CML) (Sawyers 1999, and references therein). The 
oligomerization of Bcr-Abl is essential for the activation of the tyrosine kinase activity of 
Bcr-Abl (McWhirter et al. 1993). Destroying the ability of Bcr-Abl to form tetramers or using 
the dimerization domain to disrupt Bcr-Abl activity would be a possible gene therapy 
approach for CML (Dixon et al. 2009). 
Finally, serpins (serine protease inhibitors) such as serpin ǂ1-antitrypsin function aberrantly 
as oligomers/polymers (Silverman et al. 2001; Lomas & Mahadeva 2002). In fact, the 
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polymerization of serpin ǂ1-antitrypsin is known to cause hepatocellular carcinoma and 
liver cirrhosis due to accumulation in the endoplasmatic reticulum of the liver (Lomas & 
Mahadeva 2002). Disruption of polymerization could also be targeted for gene therapy, 
using an exogenously added polymerization domain that could compete for binding to 
serpin ǂ1-antitrypsin. 
3.4 Cell compartments 
Targeting a gene therapy product to a specific subcellular compartment is another way to 
overcome disease. There are many diseases associated with protein malfunction in different 
organelles of the cell (Davis et al. 2007). For example, certain cancers can arise when a 
protein localizes to the wrong compartment. The typical example is cytoplasmically 
mislocalized p53. When p53 is in the cytoplasm, it cannot act as tumor suppressor since it is 
a transcription factor that needs to be in the nucleus in order to function (Kau et al. 2004; 
Wurzer et al. 2001). In addition to mislocation from the nucleus, the incorrect localization of 
proteins normally destined for lysosomes, peroxisomes, Golgi apparatus, endoplasmic 
reticulum (ER) or mitochondria can also lead to disease. Directing gene therapy products to 
specific subcellular compartments represents not only novel targets but a new way to 
approach gene therapy (Mossalam et al. 2010).  
3.4.1 Lysosomes 
Lysosomes degrade unused cellular constituents, receptors and release active enzymes 
extracellularly and are involved in post-translational maturation of proteins. Dysfunction of 
lysosomal hydrolases leads to loss of cell growth control and results in chemotherapy 
resistance as well as high metastatic potential (Castino et al. 2003). Furthermore, lysosome 
and lysosome-related organelles are associated with Lysosomal Storage Disease (LSD), 
Alzheimer’s disease and development of several types of tumors. LSD is collective term for 
40 genetic disorders due to single or multi enzyme deficiency which results in 
neurodegenerative disorders. Therapy options are limited to BMT and enzyme replacement. 
The disadvantages of BMT are morbidity and mortality as well as incomplete response to 
therapy. Enzyme replacement fails because of fast degradation of the enzyme from 
bloodstream. Due to these limitations, gene therapy represents a potential alternative. 
Currently, gene therapy is focused on using cargo proteins that deliver proteins to the 
lysosome. Since clathrin-dependent receptor-mediated endocytosis (RME) is the main 
transport mechanism for delivery to the lysosome, it is thought that all forms of LSDs can be 
treated with gene therapy (Bareford & Swaan 2007, and references therein).  
3.4.2 Peroxisomes 
Peroxisomes are multifunctional organelles which are involved in biochemical and 
metabolic processes such as oxidation of fatty acids, plasmalogen biosynthesis and 
glyoxylate detoxification. Malfunction of or defects in peroxisomes are associated with a 
variety of diseases which can be classified as Zellweger spectrum peroxisome biogenesis 
disorders or rhizomelic chondrodysplasia punctate. Defects in peroxisome biogenesis 
proteins (peroxins, encoded by PEX genes) can lead to eye anomalies, extreme hypotension, 
and hepatomegaly (to name a few), and usually are fatal by age 1-2. In general deficiencies 
in a single peroxisomal enzyme (PEX) are associated with a variety of diseases. The therapy 
approaches are focused on protein therapeutics, peroxisomal enzymes and gene therapy. 
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One possible gene therapy target is the antioxidant enzyme, catalase. A modified catalase 
molecule was transduced into hypocatalasemic fibroblasts and reduced hydrogen peroxide 
levels dramatically. This resulted in the restoration of oxidative balance, which may have 
cytoprotective effects (Terlecky & Koepke 2007). The cytoprotective role of catalase makes it 
an excellent gene therapy target, because many diseases such as cardiovascular diseases are 
linked to high hydrogen peroxide levels (Gong et al. 2010). 
3.4.3 Proteasome 
Targeting the proteasome, the cell’s degradation machinery, represents another possible 
target for gene therapy. The general inhibition of the proteasome is already used for 
treatment of inflammatory disease and cancer (Nalepa et al. 2006) while the activation of the 
proteasome can be used for neurodegenerative diseases and cardiac diseases (Dahlmann 
2007). Targeting disease-specific components of the ubiquitin-proteasome system provides 
the possibility for directed therapy approaches (Nalepa et al. 2006). The E3 ubiqitin ligases 
are important for specificity of proteasomal degradation because they recognize the proteins 
which should be destroyed (Nalepa et al. 2006). More classical drug targets are the 
ubiquitin-activation and the actual degradation step which occurs in the proteasome. A new 
approach suggested by our lab involves capturing oncogenic proteins such as survivin and 
sending them to the proteasome for degradation. This could be achieved by including a 
gene therapy construct that has a survivin dimerization domain and a proteasomal 
degradation domain, capable of capturing endogenous survivin and sending it to the 
proteasome (Mossalam et al. 2010). 
3.4.4 Mitochondria 
Mitochondria are essential for production of cellular ATP. The mitochondria consist of the 
outer membrane, the inner membrane, intermembrane space, cristae and mitochondrial 
DNA. Mutations in mitochondrial DNA are associated with muscle and central nervous 
system dysfunction, but only if most of the DNA is mutated. An interesting gene therapy 
approach is to tag mitochondria targeting signals to endonucleases which are able to 
degrade the mutated mitochondrial DNA. This mutant DNA contains the T8399G mutation 
which creates a unique restriction site and allows the restriction enzyme to distinguish 
between normal DNA and mutated DNA. It provides new therapy options for neuropathy, 
ataxia and retinitis pigmentosa (Srivastava & Moraes 2001). In addition, the mitochondrion 
is also essential in cellular apoptosis. Proteins such as p53 can be sent to the mitochondria, 
eventually resulting in cytochrome c release and apoptosis. Indeed, p53 targeted to the 
mitochondria has shown to cause apoptosis in different cancer cell lines (Palacios & Moll 
2006).  
3.4.5 Endoplasmic reticulum 
The endoplasmic reticulum (ER) produces almost all cellular lipids, and the majority of 
proteins are synthesized on the cytosolic surface of the ER. A wide range of diseases occur 
due to mistakes in protein folding/assembly in the ER such as CF and neurodegenerative 
diseases. CF is a classic gene therapy target with one single mutation which can be targeted 
by replacing the defect gene. Unfortunately, all gene therapy approaches for CF have failed 
thus far. Certain neurodegenerative diseases are affected by mutations in proteins involved 
in ER assembly. Mutations in Parkin, which is an E3 ligase responsible for ubiquitinylation 
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and regulation of proteasomal degradation, is associated with juvenile Parkinsonism. The 
Parkin proteasomal pathway normally degrades Pael-R in dopaminergic neurons. Pael-R 
accumulates in brain cells when Parkin is mutated (Aridor et al. 2004, and references 
therein). Adding back functional Parkin would then be a possible gene therapy approach for 
juvenile Parkinsonism.  
3.4.6 Golgi apparatus 
In addition to the synthesis of carbohydrates, the Golgi apparatus (GA) sorts as well as 
dispatch proteins to the ER. SPCA1 is a protein found in the trans-Golgi. When mutations 
occur in the gene (ATP2C1) encoding SPCA1, a genetic disorder results called Hailey-Hailey 
disease. These various mutations result in skin lesions which are usually benign and lead 
only in a few cases into squamous cell carcinoma (Pizzo et al. 2011). Replacing mutated 
SPCA1 would be a possible gene therapy approach to treat Hailey-Hailey disease.  
3.4.7 Nucleus 
Many diseases are associated with problems in nuclear import and export. For example, 
various types of cancers are associated with p53 and FOXO mislocalization in the cytoplasm, 
while their normal localization is the nucleus. There are several examples of proteins that 
when mislocalized to different compartments lose their function or may become oncogenic. 
The control of compartmentalization of key proteins can be used to overcome disease. 
Besides, tumor suppressors such as p53, cell cycle inhibitors, G-protein coupled receptors 
and transcription factors can also lose their function when mislocalized (Chinen et al. 2007). 
p21WAF-1 is localized in the nucleus where it accomplishes its function as cell cycle inhibitor. 
When moved to the cytoplasm, it is associated with tumor progression (Davis et al. 2007; 
Keeshan et al. 2003). G-protein coupled receptors like rhodopsin, vasopressin V2, LDL and 
CFTR all require proper localization for function. For example, rhodopsin is found in the 
membrane sacs within the rods, and when mislocalized it is confined in the plasma 
membrane of photoreceptor cell body and causes retinitis pigmentosa (Edwards et al. 2000). 
Additional transcription factors such as NF-κB and FOXO are both associated with various 
types of cancer when mislocalized to different compartments. NF-κB is located in the 
cytoplasm of normal cells whereas nuclear accumulation causes cancer. In contrast FOXO is 
found in the nucleus of normal cells and cytoplasmic localization results in cancer (Davis et 
al. 2007, and references therein).  
There are several different gene therapy approaches for targeting mislocalized proteins. The 
standard method is to add back the protein which contains functional localization signals, 
such as the adenoviral p53 vectors GendicineTM and OncorineTM. On the other hand, 
blocking general nuclear import or export machinery has been attempted, but due to the 
non-specific blockage of import/export, these methods suffer from toxicity. Instead of 
general inhibition of import/export, the protein itself can be modified. Adding nuclear 
localization signals (NLS) or nuclear export signals (NES) to the genes encoding 
mislocalized proteins allows targeting of proteins directly to the desired compartments.  
The localization of proteins can be changed by using a protein switch developed in our 
laboratory (Kakar et al. 2007; Davis et al. 2007). The protein switch is a plasmid encoding a 
NES, a NLS and a ligand binding domain (LBD) from steroid hormone receptor. The LBD 
serves as a ligand-inducible nuclear localization switch. The protein switch is cytoplasm in 
the absence of ligand and translocates to the nucleus when ligand is added. The protein 
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switch has also been designed to contain dimerization domain that allows capture of an 
endogenous protein of interest. Upon ligand addition, the protein switch-endogenous 
protein complex will then translocate to the nucleus. Removal of the endogenous protein 
from the cytoplasm can result in decrease cytoplasmic signaling or increased apoptotic 
signaling in the nucleus, with potential use in cancer therapy (Kakar et al. 2007). 
4. Conclusions 
Some of the major diseases currently targeted by gene therapy include cancer, 
cardiovascular disease, HIV, and monogenic diseases. Despite many decades of gene 
therapy research on these diseases, there currently are very few products that have made it 
to market. The search for new gene therapy targets and improved methods are therefore 
warranted. The integration of new and standard technologies (genome sequencing, 
microarrays, improved analysis, and linkage to molecular and biochemical assays) recently 
have yielded methods to uncover new drivers of cancer (Akavia et al. 2010). In 2008, the 
NIH started its Undiagnosed Diseases Program. These NIH investigators first try to 
diagnose an illness by first looking at known genetic markers, followed by standard 
molecular and biochemical assays. If no candidate genes are revealed, they then use state-of-
the-art genetic analyses that can sequence the entire exome (all exons in the human genome) 
of a patient and their family; high resolution microarrays can genotype the rest of the 
genome to "bring genomics to the clinic." After comparison to family data and a reference 
sequence (from the Human Genome Project), the gene causing a particular rare disease may 
be discovered (Maxmen 2011). Currently patients enrolled in this program are not cured; the 
candidate gene and corresponding protein are only identified. Small molecule inhibitors of 
these proteins can take years or decades to screen, therefore making replacement of these 
defective or mutant genes prime candidates for gene therapy treatment in patients with a 
rare disease.  
Further analysis of the protein can uncover the molecular basis of the disease. Is this protein 
a hub protein which interacts with many other proteins? What are the protein-protein 
interactions that govern its activity? Are there any cell compartmentalization abnormalities 
that promote disease? With this information in mind, more modern gene therapy 
approaches can be developed. In our laboratory, we have designed a protein switch 
designed to capture and change location of a harmful protein in a cell. This altered location 
could be exploited for disease therapy. For example, the Bcr-Abl protein is oncogenic in the 
cytoplasm, but causes apoptosis when moved to the nucleus (Dixon et al. 2009). A protein 
switch against Bcr-Abl is being developed in our laboratory that can dimerize to wild type 
(wt) Bcr-Abl by virtue of a coiled-coil dimerization domain (Mossalam et al. 2010). The 
protein switch also contains a ligand-inducible domain that can move the protein from the 
cytoplasm to the nucleus upon the addition of ligand (Kakar et al. 2007). Therefore, after 
capture, wt Bcr-Abl is dragged to the nucleus, where apoptosis ensues. Understanding the 
molecular mechanisms that govern protein activity can therefore be used as the next phase 
in gene therapy, where altered protein location can completely change the function of a 
protein. Other emerging modern gene therapy-based approaches including anti-gene 
therapies (antisense, siRNA, ribozymes) and immunotherapy are desired to have a 
significant impact on disease treatment. 
www.intechopen.com
 
Targets in Gene Therapy 
 
20
5. References 
Abo-Auda, W., and R. L. Benza. 2003. Therapeutic angiogenesis: review of current concepts 
and future directions. J Heart Lung Transplant 22 (4):370-82. 
Akavia, U. D., O. Litvin, J. Kim, F. Sanchez-Garcia, D. Kotliar, H. C. Causton, P. Pochanard, 
E. Mozes, L. A. Garraway, and D. Pe'er. 2010. An integrated approach to uncover 
drivers of cancer. Cell 143 (6):1005-17. 
Altieri, D. C. 2001. The molecular basis and potential role of survivin in cancer diagnosis 
and therapy. Trends Mol Med 7 (12):542-7. 
Altieri, D. C. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (1):46-
54. 
Altieri, D. C. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev 
Cancer 8 (1):61-70. 
Antoine, C., S. Muller, A. Cant, M. Cavazzana-Calvo, P. Veys, J. Vossen, A. Fasth, C. 
Heilmann, N. Wulffraat, R. Seger, S. Blanche, W. Friedrich, M. Abinun, G. Davies, 
R. Bredius, A. Schulz, P. Landais, and A. Fischer. 2003. Long-term survival and 
transplantation of haemopoietic stem cells for immunodeficiencies: report of the 
European experience 1968-99. Lancet 361 (9357):553-60. 
Aridor, M., A. K. Guzik, A. Bielli, and K. N. Fish. 2004. Endoplasmic reticulum export site 
formation and function in dendrites. J Neurosci 24 (15):3770-6. 
Arnett, D. K., A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. 
Herrington, Y. Hong, C. Jaquish, D. A. McDermott, and C. J. O'Donnell. 2007. 
Relevance of genetics and genomics for prevention and treatment of cardiovascular 
disease: a scientific statement from the American Heart Association Council on 
Epidemiology and Prevention, the Stroke Council, and the Functional Genomics 
and Translational Biology Interdisciplinary Working Group. Circulation 115 
(22):2878-901. 
Bareford, L. M., and P. W. Swaan. 2007. Endocytic mechanisms for targeted drug delivery. 
Adv Drug Deliv Rev 59 (8):748-58. 
Baumgartner, I., N. Chronos, A. Comerota, T. Henry, J. P. Pasquet, F. Finiels, A. Caron, J. F. 
Dedieu, R. Pilsudski, and P. Delaere. 2009. Local gene transfer and expression 
following intramuscular administration of FGF-1 plasmid DNA in patients with 
critical limb ischemia. Mol Ther 17 (5):914-21. 
Beaupre, D. M., and R. Kurzrock. 1999. RAS and leukemia: from basic mechanisms to gene-
directed therapy. J Clin Oncol 17 (3):1071-9. 
Boucher, R. C., C. U. Cotton, J. T. Gatzy, M. R. Knowles, and J. R. Yankaskas. 1988. Evidence 
for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary 
cell cultures. J Physiol 405:77-103. 
Buckley, R. H., R. I. Schiff, S. E. Schiff, M. L. Markert, L. W. Williams, T. O. Harville, J. L. 
Roberts, and J. M. Puck. 1997. Human severe combined immunodeficiency: genetic, 
phenotypic, and functional diversity in one hundred eight infants. J Pediatr 130 
(3):378-87. 
Cao, A., and R. Galanello. 2010. Beta-thalassemia. Genet Med 12 (2):61-76. 
CardioVascular BioTherapeutics, Inc. 2011. Fibroblast Growth Factor-1 (FGF-1) for the Treatment 
of Coronary Heart Disease (ACORD)  [cited 03/2011 2011]. Available from 
http://www.clinicaltrials.gov/ct2/show/NCT00117936?term=henry+FGF&rank=1. 
www.intechopen.com
 
Choosing Targets for Gene Therapy 
 
21 
Castino, R., M. Demoz, and C. Isidoro. 2003. Destination 'lysosome': a target organelle for 
tumour cell killing? J Mol Recognit 16 (5):337-48. 
Cavazzana-Calvo, M., S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. Nusbaum, F. 
Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, F. L. Deist, and A. Fischer. 2000. 
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. 
Science 288 (5466):669-72. 
Cavazzana-Calvo, M., E. Payen, O. Negre, G. Wang, K. Hehir, F. Fusil, J. Down, M. Denaro, 
T. Brady, K. Westerman, R. Cavallesco, B. Gillet-Legrand, L. Caccavelli, R. Sgarra, 
L. Maouche-Chretien, F. Bernaudin, R. Girot, R. Dorazio, G. J. Mulder, A. Polack, 
A. Bank, J. Soulier, J. Larghero, N. Kabbara, B. Dalle, B. Gourmel, G. Socie, S. 
Chretien, N. Cartier, P. Aubourg, A. Fischer, K. Cornetta, F. Galacteros, Y. Beuzard, 
E. Gluckman, F. Bushman, S. Hacein-Bey-Abina, and P. Leboulch. 2010. 
Transfusion independence and HMGA2 activation after gene therapy of human 
beta-thalassaemia. Nature 467 (7313):318-22. 
Cerepro, EMEA recommendation on. 2009. European Medicines Agency recommendation 
on Cerepro. 
Chene, P. 2001. The role of tetramerization in p53 function. Oncogene 20 (21):2611-7. 
Chinen, J., J. Davis, S. S. De Ravin, B. N. Hay, A. P. Hsu, G. F. Linton, N. Naumann, E. Y. 
Nomicos, C. Silvin, J. Ulrick, N. L. Whiting-Theobald, H. L. Malech, and J. M. Puck. 
2007. Gene therapy improves immune function in preadolescents with X-linked 
severe combined immunodeficiency. Blood 110 (1):67-73. 
Chiuve, S. E., M. L. McCullough, F. M. Sacks, and E. B. Rimm. 2006. Healthy lifestyle factors 
in the primary prevention of coronary heart disease among men: benefits among 
users and nonusers of lipid-lowering and antihypertensive medications. Circulation 
114 (2):160-7. 
Cloutier, M. M., L. Guernsey, P. Mattes, and B. Koeppen. 1990. Duramycin enhances 
chloride secretion in airway epithelium. Am J Physiol 259 (3 Pt 1):C450-4. 
Consortium, International HapMap. 2003. The International HapMap Project. Nature 426 
(6968):789-96. 
Crick, F. H. 1952. Is alpha-keratin a coiled coil? Nature 170 (4334):882-3. 
Dahlmann, B. 2007. Role of proteasomes in disease. BMC Biochem 8 Suppl 1:S3. 
Davis, J. R., M. Kakar, and C. S. Lim. 2007. Controlling protein compartmentalization to 
overcome disease. Pharm Res 24 (1):17-27. 
De Ravin, S. S., and H. L. Malech. 2009. Partially corrected X-linked severe combined 
immunodeficiency: long-term problems and treatment options. Immunol Res 43 (1-
3):223-42. 
Dixon, A. S., M. Kakar, K. M. Schneider, J. E. Constance, B. C. Paullin, and C. S. Lim. 2009. 
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to 
the nucleus causes apoptosis. J Control Release 140 (3):245-9. 
Duggan, D. J., M. Bittner, Y. Chen, P. Meltzer, and J. M. Trent. 1999. Expression profiling 
using cDNA microarrays. Nat Genet 21 (1 Suppl):10-4. 
Edelstein, M. L., M. R. Abedi, and J. Wixon. 2007. Gene therapy clinical trials worldwide to 
2007--an update. J Gene Med 9 (10):833-42. 
Edelstein, M. L., M. R. Abedi, J. Wixon, and R. M. Edelstein. 2004. Gene therapy clinical 
trials worldwide 1989-2004-an overview. J Gene Med 6 (6):597-602. 
www.intechopen.com
 
Targets in Gene Therapy 
 
22
Edwards, S. W., C. M. Tan, and L. E. Limbird. 2000. Localization of G-protein-coupled 
receptors in health and disease. Trends Pharmacol Sci 21 (8):304-8. 
Erster, S., M. Mihara, R. H. Kim, O. Petrenko, and U. M. Moll. 2004. In vivo mitochondrial 
p53 translocation triggers a rapid first wave of cell death in response to DNA 
damage that can precede p53 target gene activation. Mol Cell Biol 24 (15):6728-41. 
Flume, P. A., P. J. Mogayzel Jr, K. A. Robinson, R. L. Rosenblatt, L. Quittell, B. C. Marshall, 
and Committee Clinical Practice Guidelines For Pulmonary Therapies. 2010. Cystic 
Fibrosis Pulmonary Guidelines: Pulmonary Complications: Hemoptysis and 
Pneumothorax. Am J Respir Crit Care Med. 
Flynn, A., and T. O'Brien. 2008. Alferminogene tadenovec, an angiogenic FGF4 gene therapy 
for coronary artery disease. IDrugs 11 (4):283-93. 
Foundation, Cystic Fibrosis. 2011. Cystic Fibrosis Foundation  2011 [cited 01/18/2011 2011]. 
Available from http://www.cff.org/. 
Garber, K. 2006. China approves world's first oncolytic virus therapy for cancer treatment. J 
Natl Cancer Inst 98 (5):298-300. 
Glover, J. N., and S. C. Harrison. 1995. Crystal structure of the heterodimeric bZIP 
transcription factor c-Fos-c-Jun bound to DNA. Nature 373 (6511):257-61. 
Goh, A. M., C. R. Coffill, and D. P. Lane. 2010. The role of mutant p53 in human cancer. J 
Pathol. 
Goh, A. M., C. R. Coffill, and D. P. Lane. 2011. The role of mutant p53 in human cancer. J 
Pathol 223 (2):116-26. 
Gong, G., Y. Qin, W. Huang, S. Zhou, X. Wu, X. Yang, Y. Zhao, and D. Li. 2010. Protective 
effects of diosgenin in the hyperlipidemic rat model and in human vascular 
endothelial cells against hydrogen peroxide-induced apoptosis. Chem Biol Interact 
184 (3):366-75. 
Gorner, K., E. Holtorf, J. Waak, T. T. Pham, D. M. Vogt-Weisenhorn, W. Wurst, C. Haass, 
and P. J. Kahle. 2007. Structural determinants of the C-terminal helix-kink-helix 
motif essential for protein stability and survival promoting activity of DJ-1. J Biol 
Chem 282 (18):13680-91. 
Grossman, D., and D. C. Altieri. 2001. Drug resistance in melanoma: mechanisms, apoptosis, 
and new potential therapeutic targets. Cancer Metastasis Rev 20 (1-2):3-11. 
Guo, J., and H. Xin. 2006. Chinese gene therapy. Splicing out the West? Science 314 
(5803):1232-5. 
Guo, Z. S., S. H. Thorne, and D. L. Bartlett. 2008. Oncolytic virotherapy: molecular targets in 
tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. 
Biochim Biophys Acta 1785 (2):217-31. 
Hacein-Bey-Abina, S., F. Le Deist, F. Carlier, C. Bouneaud, C. Hue, J. P. De Villartay, A. J. 
Thrasher, N. Wulffraat, R. Sorensen, S. Dupuis-Girod, A. Fischer, E. G. Davies, W. 
Kuis, L. Leiva, and M. Cavazzana-Calvo. 2002. Sustained correction of X-linked 
severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346 
(16):1185-93. 
Harvey, B. G., P. L. Leopold, N. R. Hackett, T. M. Grasso, P. M. Williams, A. L. Tucker, R. J. 
Kaner, B. Ferris, I. Gonda, T. D. Sweeney, R. Ramalingam, I. Kovesdi, S. Shak, and 
R. G. Crystal. 1999. Airway epithelial CFTR mRNA expression in cystic fibrosis 
patients after repetitive administration of a recombinant adenovirus. J Clin Invest 
104 (9):1245-55. 
www.intechopen.com
 
Choosing Targets for Gene Therapy 
 
23 
Haupt, S., M. Berger, Z. Goldberg, and Y. Haupt. 2003. Apoptosis - the p53 network. J Cell 
Sci 116 (Pt 20):4077-85. 
Henderson, B. R. 2005. Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking. 
Bioessays 27 (9):884-93. 
Hirschhorn, J. N., and M. J. Daly. 2005. Genome-wide association studies for common 
diseases and complex traits. Nat Rev Genet 6 (2):95-108. 
Jeffrey, P. D., S. Gorina, and N. P. Pavletich. 1995. Crystal structure of the tetramerization 
domain of the p53 tumor suppressor at 1.7 angstroms. Science 267 (5203):1498-502. 
Kakar, M., J. R. Davis, S. E. Kern, and C. S. Lim. 2007. Optimizing the protein switch: 
altering nuclear import and export signals, and ligand binding domain. J Control 
Release 120 (3):220-32. 
Kamada, R., T. Nomura, C. W. Anderson, and K. Sakaguchi. 2011. Cancer-associated p53 
tetramerization domain mutants: quantitative analysis reveals a low threshold for 
tumor suppressor inactivation. J Biol Chem 286 (1):252-8. 
Kass, R. W., M. N. Kotler, and S. Yazdanfar. 1992. Stimulation of coronary collateral growth: 
current developments in angiogenesis and future clinical applications. Am Heart J 
123 (2):486-96. 
Kato, J., Y. Kuwabara, M. Mitani, N. Shinoda, A. Sato, T. Toyama, A. Mitsui, T. Nishiwaki, S. 
Moriyama, J. Kudo, and Y. Fujii. 2001. Expression of survivin in esophageal cancer: 
correlation with the prognosis and response to chemotherapy. Int J Cancer 95 (2): 
92-5. 
Kau, T. R., J. C. Way, and P. A. Silver. 2004. Nuclear transport and cancer: from mechanism 
to intervention. Nat Rev Cancer 4 (2):106-17. 
Keeshan, K., T. G. Cotter, and S. L. McKenna. 2003. Bcr-Abl upregulates cytosolic p21WAF-
1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J 
Haematol 123 (1):34-44. 
Kerem, B., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, M. 
Buchwald, and L. C. Tsui. 1989. Identification of the cystic fibrosis gene: genetic 
analysis. Science 245 (4922):1073-80. 
Keskin, O., and R. Nussinov. 2007. Similar binding sites and different partners: implications 
to shared proteins in cellular pathways. Structure 15 (3):341-54. 
Kim, P. M., L. J. Lu, Y. Xia, and M. B. Gerstein. 2006. Relating three-dimensional structures 
to protein networks provides evolutionary insights. Science 314 (5807):1938-41. 
Kitchen, S. G., S. Shimizu, and D. S. An. 2011. Stem cell-based anti-HIV gene therapy. 
Virology 411 (2):260-72. 
Knowlton, R. G., O. Cohen-Haguenauer, N. Van Cong, J. Frezal, V. A. Brown, D. Barker, J. 
C. Braman, J. W. Schumm, L. C. Tsui, M. Buchwald, and et al. 1985. A polymorphic 
DNA marker linked to cystic fibrosis is located on chromosome 7. Nature 318 
(6044):380-2. 
Kobayashi, N., K. Agematsu, K. Sugita, M. Sako, S. Nonoyama, A. Yachie, S. Kumaki, S. 
Tsuchiya, H. D. Ochs, Y. Fukushima, and A. Komiyama. 2003. Novel Artemis gene 
mutations of radiosensitive severe combined immunodeficiency in Japanese 
families. Hum Genet 112 (4):348-52. 
Krishna, S. S., I. Majumdar, and N. V. Grishin. 2003. Structural classification of zinc fingers: 
survey and summary. Nucleic Acids Res 31 (2):532-50. 
www.intechopen.com
 
Targets in Gene Therapy 
 
24
Kung, C., J. T. Pingel, M. Heikinheimo, T. Klemola, K. Varkila, L. I. Yoo, K. Vuopala, M. 
Poyhonen, M. Uhari, M. Rogers, S. H. Speck, T. Chatila, and M. L. Thomas. 2000. 
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined 
immunodeficiency disease. Nat Med 6 (3):343-5. 
Landschulz, W. H., P. F. Johnson, and S. L. McKnight. 1988. The leucine zipper: a 
hypothetical structure common to a new class of DNA binding proteins. Science 240 
(4860):1759-64. 
Li, F., G. Ambrosini, E. Y. Chu, J. Plescia, S. Tognin, P. C. Marchisio, and D. C. Altieri. 1998. 
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 
(6711):580-4. 
Li, J., L. Simpson, M. Takahashi, C. Miliaresis, M. P. Myers, N. Tonks, and R. Parsons. 1998. 
The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the 
AKT/protein kinase B oncogene. Cancer Res 58 (24):5667-72. 
Li, J., and J. Yuan. 2008. Caspases in apoptosis and beyond. Oncogene 27 (48):6194-206. 
Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. 
Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 
coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 
infection. Cell 86 (3):367-77. 
Lockley, M., M. Fernandez, Y. Wang, N. F. Li, S. Conroy, N. Lemoine, and I. McNeish. 2006. 
Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: 
comparison with E1A wild-type viruses, bioluminescence monitoring, and 
intraperitoneal delivery in icodextrin. Cancer Res 66 (2):989-98. 
Lomas, D. A., and R. Mahadeva. 2002. Alpha1-antitrypsin polymerization and the 
serpinopathies: pathobiology and prospects for therapy. J Clin Invest 110 (11):1585-
90. 
Lomas, David A., and Ravi Mahadeva. 2002. ǂ1-Antitrypsin polymerization and the 
serpinopathies: pathobiology and prospects for therapy. The Journal of Clinical 
Investigation 110 (11):1585-1590. 
Lucarelli, G., and J. Gaziev. 2008. Advances in the allogeneic transplantation for thalassemia. 
Blood Rev 22 (2):53-63. 
Malik, P., and P. I. Arumugam. 2005. Gene Therapy for beta-thalassemia. Hematology Am Soc 
Hematol Educ Program:45-50. 
Mason, J. M., and K. M. Arndt. 2004. Coiled coil domains: stability, specificity, and 
biological implications. Chembiochem 5 (2):170-6. 
Maulik, N. 2009. NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the 
treatment of intermittent claudication and critical limb ischemia. Curr Opin Investig 
Drugs 10 (3):259-68. 
Maxmen, A. 2011. Exome sequencing deciphers rare diseases. Cell 144 (5):635-7. 
McCarty, A. S., G. Kleiger, D. Eisenberg, and S. T. Smale. 2003. Selective dimerization of a 
C2H2 zinc finger subfamily. Mol Cell 11 (2):459-70. 
McPhail, G. L., J. D. Acton, M. C. Fenchel, R. S. Amin, and M. Seid. 2008. Improvements in 
lung function outcomes in children with cystic fibrosis are associated with better 
nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. 
J Pediatr 153 (6):752-7. 
www.intechopen.com
 
Choosing Targets for Gene Therapy 
 
25 
McWhirter, J. R., D. L. Galasso, and J. Y. Wang. 1993. A coiled-coil oligomerization domain 
of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell 
Biol 13 (12):7587-95. 
Mesri, M., N. R. Wall, J. Li, R. W. Kim, and D. C. Altieri. 2001. Cancer gene therapy using a 
survivin mutant adenovirus. J Clin Invest 108 (7):981-90. 
Metcalfe, K. A., H. T. Lynch, P. Ghadirian, N. Tung, I. A. Olivotto, W. D. Foulkes, E. Warner, 
O. Olopade, A. Eisen, B. Weber, J. McLennan, P. Sun, and S. A. Narod. 2005. The 
risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol 
Oncol 96 (1):222-6. 
Mitchell, P. 2010. Ark's gene therapy stumbles at the finish line. Nat Biotechnol 28 (3):183-4. 
Morishita, R., M. Aoki, N. Hashiya, H. Makino, K. Yamasaki, J. Azuma, Y. Sawa, H. 
Matsuda, Y. Kaneda, and T. Ogihara. 2004. Safety evaluation of clinical gene 
therapy using hepatocyte growth factor to treat peripheral arterial disease. 
Hypertension 44 (2):203-9. 
Moss, R. B., C. Milla, J. Colombo, F. Accurso, P. L. Zeitlin, J. P. Clancy, L. T. Spencer, J. 
Pilewski, D. A. Waltz, H. L. Dorkin, T. Ferkol, M. Pian, B. Ramsey, B. J. Carter, D. B. 
Martin, and A. E. Heald. 2007. Repeated aerosolized AAV-CFTR for treatment of 
cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 18 
(8):726-32. 
Moss, R. B., D. Rodman, L. T. Spencer, M. L. Aitken, P. L. Zeitlin, D. Waltz, C. Milla, A. S. 
Brody, J. P. Clancy, B. Ramsey, N. Hamblett, and A. E. Heald. 2004. Repeated 
adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane 
regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, 
double-blind, placebo-controlled trial. Chest 125 (2):509-21. 
Mossalam, M., A. S. Dixon, and C. S. Lim. 2010. Controlling subcellular delivery to optimize 
therapeutic effect. Ther Deliv 1 (1):169-193. 
Murre, C., G. Bain, M. A. van Dijk, I. Engel, B. A. Furnari, M. E. Massari, J. R. Matthews, M. 
W. Quong, R. R. Rivera, and M. H. Stuiver. 1994. Structure and function of helix-
loop-helix proteins. Biochim Biophys Acta 1218 (2):129-35. 
Nakamura, Y. 2009. DNA variations in human and medical genetics: 25 years of my 
experience. J Hum Genet 54 (1):1-8. 
Nalepa, G., M. Rolfe, and J. W. Harper. 2006. Drug discovery in the ubiquitin-proteasome 
system. Nat Rev Drug Discov 5 (7):596-613. 
NCBI. 2011. Microarrays: Chipping away at the Mysteries of science and medicine  2007 [cited 
03/2011 2011]. Available from 
http://www.ncbi.nlm.nih.gov/About/primer/microarrays.html. 
O'Connor, D. S., D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, P. C. Marchisio, 
and D. C. Altieri. 2000. Regulation of apoptosis at cell division by p34cdc2 
phosphorylation of survivin. Proc Natl Acad Sci U S A 97 (24):13103-7. 
Palacios, G., and U. M. Moll. 2006. Mitochondrially targeted wild-type p53 suppresses 
growth of mutant p53 lymphomas in vivo. Oncogene 25 (45):6133-9. 
Peng, Z. 2005. Current status of gendicine in China: recombinant human Ad-p53 agent for 
treatment of cancers. Hum Gene Ther 16 (9):1016-27. 
Pizzo, P., V. Lissandron, P. Capitanio, and T. Pozzan. 2011. Ca(2+) signalling in the Golgi 
apparatus. Cell Calcium. 
www.intechopen.com
 
Targets in Gene Therapy 
 
26
Powell, R. J., M. Simons, F. O. Mendelsohn, G. Daniel, T. D. Henry, M. Koga, R. Morishita, 
and B. H. Annex. 2008. Results of a double-blind, placebo-controlled study to 
assess the safety of intramuscular injection of hepatocyte growth factor plasmid to 
improve limb perfusion in patients with critical limb ischemia. Circulation 118 
(1):58-65. 
Project, Human Genome. 2011. Human Genome Project 2011]. Available from 
http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml. 
Project, The International HapMap. 426. The International HapMap Project (2003/12/20), Dec 
18 2003 [cited 6968 426]. Available from  
 http://www.ncbi.nlm.nih.gov/pubmed/14685227. 
Puel, A., S. F. Ziegler, R. H. Buckley, and W. J. Leonard. 1998. Defective IL7R expression in 
T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 20 (4):394-7. 
Raty, J. K., J. T. Pikkarainen, T. Wirth, and S. Yla-Herttuala. 2008. Gene therapy: the first 
approved gene-based medicines, molecular mechanisms and clinical indications. 
Curr Mol Pharmacol 1 (1):13-23. 
Riferminogene pecaplasmide. 2010. Am J Cardiovasc Drugs 10 (5):343-6. 
Rodriguez, J. A., S. Schuchner, W. W. Au, M. Fabbro, and B. R. Henderson. 2004. Nuclear-
cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is 
regulated by dimerization with BRCA1. Oncogene 23 (10):1809-20. 
Roth, J. A., D. Nguyen, D. D. Lawrence, B. L. Kemp, C. H. Carrasco, D. Z. Ferson, W. K. 
Hong, R. Komaki, J. J. Lee, J. C. Nesbitt, K. M. Pisters, J. B. Putnam, R. Schea, D. M. 
Shin, G. L. Walsh, M. M. Dolormente, C. I. Han, F. D. Martin, N. Yen, K. Xu, L. C. 
Stephens, T. J. McDonnell, T. Mukhopadhyay, and D. Cai. 1996. Retrovirus-
mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat 
Med 2 (9):985-91. 
Ryan, B. M., N. O'Donovan, and M. J. Duffy. 2009. Survivin: a new target for anti-cancer 
therapy. Cancer Treat Rev 35 (7):553-62. 
Ryser, O., A. Morell, and W. H. Hitzig. 1988. Primary immunodeficiencies in Switzerland: 
first report of the national registry in adults and children. J Clin Immunol 8 (6):479-
85. 
Sawyers, C. L. 1999. Chronic myeloid leukemia. N Engl J Med 340 (17):1330-40. 
Schwarz, K., G. H. Gauss, L. Ludwig, U. Pannicke, Z. Li, D. Lindner, W. Friedrich, R. A. 
Seger, T. E. Hansen-Hagge, S. Desiderio, M. R. Lieber, and C. R. Bartram. 1996. 
RAG mutations in human B cell-negative SCID. Science 274 (5284):97-9. 
Shi, J., and D. Zheng. 2009. An update on gene therapy in China. Curr Opin Mol Ther 11 
(5):547-53. 
Shigematsu, H., K. Yasuda, T. Iwai, T. Sasajima, S. Ishimaru, Y. Ohashi, T. Yamaguchi, T. 
Ogihara, and R. Morishita. 2010. Randomized, double-blind, placebo-controlled 
clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene 
Ther 17 (9):1152-61. 
Shiraishi, K., S. Kato, S. Y. Han, W. Liu, K. Otsuka, M. Sakayori, T. Ishida, M. Takeda, R. 
Kanamaru, N. Ohuchi, and C. Ishioka. 2004. Isolation of temperature-sensitive p53 
mutations from a comprehensive missense mutation library. J Biol Chem 279 (1):348-
55. 
www.intechopen.com
 
Choosing Targets for Gene Therapy 
 
27 
Siegmund, K. H., U. E. Steiner, and C. Richert. 2003. ChipCheck--a program predicting total 
hybridization equilibria for DNA binding to small oligonucleotide microarrays. J 
Chem Inf Comput Sci 43 (6):2153-62. 
Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A. 
Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, P. A. Pemberton, E. Remold-
O'Donnell, G. S. Salvesen, J. Travis, and J. C. Whisstock. 2001. The serpins are an 
expanding superfamily of structurally similar but functionally diverse proteins. 
Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J 
Biol Chem 276 (36):33293-6. 
Srivastava, S., and C. T. Moraes. 2001. Manipulating mitochondrial DNA heteroplasmy by a 
mitochondrially targeted restriction endonuclease. Hum Mol Genet 10 (26):3093-9. 
Sun, H. X., H. W. He, S. H. Zhang, T. G. Liu, K. H. Ren, Q. Y. He, and R. G. Shao. 2009. 
Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of 
HepG2 cells to vincristine-induced growth inhibition. Cancer Gene Ther 16 (9):693-
702. 
Symonds, G. P., H. A. Johnstone, M. L. Millington, M. P. Boyd, B. P. Burke, and L. R. Breton. 
2010. The use of cell-delivered gene therapy for the treatment of HIV/AIDS. 
Immunol Res 48 (1-3):84-98. 
Taha, T. A., W. Osta, L. Kozhaya, J. Bielawski, K. R. Johnson, W. E. Gillanders, G. S. Dbaibo, 
Y. A. Hannun, and L. M. Obeid. 2004. Down-regulation of sphingosine kinase-1 by 
DNA damage: dependence on proteases and p53. J Biol Chem 279 (19):20546-54. 
Tehrani, A. M., S. K. Hwang, T. H. Kim, C. S. Cho, J. Hua, W. S. Nah, J. T. Kwon, J. S. Kim, S. 
H. Chang, K. N. Yu, S. J. Park, D. R. Bhandari, K. H. Lee, G. H. An, G. R. Beck, Jr., 
and M. H. Cho. 2007. Aerosol delivery of Akt controls protein translation in the 
lungs of dual luciferase reporter mice. Gene Ther 14 (5):451-8. 
Tembe, V., and B. R. Henderson. 2007. BARD1 translocation to mitochondria correlates with 
Bax oligomerization, loss of mitochondrial membrane potential, and apoptosis. J 
Biol Chem 282 (28):20513-22. 
Terlecky, S. R., and J. I. Koepke. 2007. Drug delivery to peroxisomes: employing unique 
trafficking mechanisms to target protein therapeutics. Adv Drug Deliv Rev 59 
(8):739-47. 
Testa, J. R., and A. Bellacosa. 2001. AKT plays a central role in tumorigenesis. Proc Natl Acad 
Sci U S A 98 (20):10983-5. 
Thrasher, A. J., S. Hacein-Bey-Abina, H. B. Gaspar, S. Blanche, E. G. Davies, K. Parsley, K. 
Gilmour, D. King, S. Howe, J. Sinclair, C. Hue, F. Carlier, C. von Kalle, G. de Saint 
Basile, F. le Deist, A. Fischer, and M. Cavazzana-Calvo. 2005. Failure of SCID-X1 
gene therapy in older patients. Blood 105 (11):4255-7. 
van Putten, E. H., C. M. Dirven, M. J. van den Bent, and M. L. Lamfers. 2010. Sitimagene 
ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. 
Future Oncol 6 (11):1691-710. 
Vaseva, A. V., N. D. Marchenko, and U. M. Moll. 2009. The transcription-independent 
mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in 
tumor cells. Cell Cycle 8 (11):1711-9. 
Ventura, A., D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. 
Newman, E. E. Reczek, R. Weissleder, and T. Jacks. 2007. Restoration of p53 
function leads to tumour regression in vivo. Nature 445 (7128):661-5. 
www.intechopen.com
 
Targets in Gene Therapy 
 
28
Vita, M., and M. Henriksson. 2006. The Myc oncoprotein as a therapeutic target for human 
cancer. Semin Cancer Biol 16 (4):318-30. 
Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408 
(6810):307-10. 
Weatherall, D. J. 1976. Molecular pathology of the thalassemia disorders. West J Med 124 
(5):388-402. 
WHO. 2011. Cancer  20112011]. Available from 
http://www.who.int/mediacentre/factsheets/fs297/en/. 
Wolfe, S. A., L. Nekludova, and C. O. Pabo. 2000. DNA recognition by Cys2His2 zinc finger 
proteins. Annu Rev Biophys Biomol Struct 29:183-212. 
Wood, B. P. 1997. Cystic fibrosis: 1997. Radiology 204 (1):1-10. 
Wurzer, G., W. Mosgoeller, M. Chabicovsky, C. Cerni, and J. Wesierska-Gadek. 2001. 
Nuclear Ras: unexpected subcellular distribution of oncogenic forms. J Cell Biochem 
Suppl Suppl 36:1-11. 
Xin, H. 2006. Chinese gene therapy. Gendicine's efficacy: hard to translate. Science 314 
(5803):1233. 
Xue, W., L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-
Cardo, and S. W. Lowe. 2007. Senescence and tumour clearance is triggered by p53 
restoration in murine liver carcinomas. Nature 445 (7128):656-60. 
Yu, W., and H. Fang. 2007. Clinical trials with oncolytic adenovirus in China. Curr Cancer 
Drug Targets 7 (2):141-8. 
Zhao, J., T. Tenev, L. M. Martins, J. Downward, and N. R. Lemoine. 2000. The ubiquitin-
proteasome pathway regulates survivin degradation in a cell cycle-dependent 
manner. J Cell Sci 113 Pt 23:4363-71 
www.intechopen.com
Targets in Gene Therapy
Edited by Prof. Yongping You
ISBN 978-953-307-540-2
Hard cover, 436 pages
Publisher InTech
Published online 23, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book aims at providing an up-to-date report to cover key aspects of existing problems in the emerging
field of targets in gene therapy. With the contributions in various disciplines of gene therapy, the book brings
together major approaches: Target Strategy in Gene Therapy, Gene Therapy of Cancer and Gene Therapy of
Other Diseases. This source enables clinicians and researchers to select and effectively utilize new
translational approaches in gene therapy and analyze the developments in target strategy in gene therapy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Karina J. Matissek, Ruben R. Bender, James R. Davis and Carol S. Lim (2011). Choosing Targets for Gene
Therapy, Targets in Gene Therapy, Prof. Yongping You (Ed.), ISBN: 978-953-307-540-2, InTech, Available
from: http://www.intechopen.com/books/targets-in-gene-therapy/choosing-targets-for-gene-therapy
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
